Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 8/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | BRAF | P15056 | 7/20 | 0.36 |
| ▸ | KDR | P35968 | 5/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | GABRE | P78334 | 1/20 | 0.35 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.35 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.35 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12329785 | 0.87 | NR4A1 (0.45) | RAF1EPHX2BRAFKDRGABRA1 | |
| SCHEMBL9979939 | 0.84 | RAF1 (0.41) | RAF1EPHX2BRAFKDRMAPK14 | |
| SCHEMBL2028320 | 0.83 | MAPK14 (0.43) | RAF1EPHX2BRAFKDRGABRA1 | |
| SCHEMBL4202008 | 0.83 | RAF1 (0.44) | RAF1EPHX2BRAFKDRGABRA1 | |
| SCHEMBL13230560 | 0.81 | KDR (0.56) | RAF1EPHX2BRAFKDRMAPK14 | |
| SCHEMBL2886711 | 0.80 | MAPT (0.40) | RAF1EPHX2BRAFKDR | |
| SCHEMBL2892341 | 0.79 | RAF1 (0.42) | RAF1EPHX2BRAFKDRMAPK14 | |
| SCHEMBL12852960 | 0.74 | RAF1 (0.54) | RAF1EPHX2BRAFKDRMAPK14 | |
| SCHEMBL3882564 | 0.72 | GABRG2 (0.45) | RAF1EPHX2GABRA1GABRG2GABRB3 | |
| SCHEMBL545151 | 0.72 | KDM4E (0.45) | RAF1EPHX2BRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120308651-A1 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | NOVARTIS AG | 2012-12-06 | — | — | US | disclosed |
| US-8324389-B2 | Solid forms of a Raf kinase inhibitor | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8202998-B2 | Salts of benzimidazolyl pyridyl ethers and formulations thereof | NOVARTIS AG (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100256375-A1 | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF PREPARATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100234394-A1 | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100209418-A1 | Solid Forms of a Raf Kinase Inhibitor | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| US-7767820-B2 | Substituted benzimidazoles and methods of preparation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100168060-A1 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| US-7732465-B2 | Substituted benzimidazoles and methods of their use | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100040677-A1 | FORMULATIONS FOR BENZIMIDAZOLYL PYRIDYL ETHERS | NOVARTIS AG (CH) | 2010-02-18 | — | — | US | disclosed |
| US-20090170904-A1 | Substituted benzimidazoles and methods of their use | NOVARTIS AG | 2009-07-02 | — | — | US | disclosed |
| US-20080287682-A1 | Substituted benzimidazoles and methods of preparation | NOVARTIS AG | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256375-A1 | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF PREPARATION | ABL1, CDK2, KIT | RAF1 73/4885EPHX2 2695/4885BRAF 29/4885 |
| US-20120308651-A1 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | PIR, BRD8, PHOSPHO1 | RAF1 874/4885EPHX2 2759/4885BRAF 542/4885 |
| US-20100209418-A1 | Solid Forms of a Raf Kinase Inhibitor | BRAF, RAF1, ARAF | RAF1 2/4885EPHX2 3225/4885BRAF 1/4885 |
| US-20100040677-A1 | FORMULATIONS FOR BENZIMIDAZOLYL PYRIDYL ETHERS | PIR, TP53RK, ALK | RAF1 636/4885EPHX2 2076/4885BRAF 174/4885 |
| US-20100234394-A1 | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF THEIR USE | BRAF, DSTYK, CHEK2 | RAF1 57/4885EPHX2 4169/4885BRAF 1/4885 |
| US-20100168060-A1 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | PIR, BRD8, PHOSPHO1 | RAF1 874/4885EPHX2 2759/4885BRAF 542/4885 |
| US-20090170904-A1 | Substituted benzimidazoles and methods of their use | BRAF, DSTYK, CHEK2 | RAF1 57/4885EPHX2 4169/4885BRAF 1/4885 |
| US-20080287682-A1 | Substituted benzimidazoles and methods of preparation | ABL1, CDK2, KIT | RAF1 73/4885EPHX2 2695/4885BRAF 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.